Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open-label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma

NCT03625037 is registered in ClinicalTrials.gov with Genmab as lead sponsor.

NCT NCT03625037
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03625037 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open-label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma
Lead sponsor
Genmab
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
June 26, 2018
Completion date
January 31, 2029
Enrollment
666 (actual)
Sites
85

Conditions

As the registry lists them; a condition with its own page is linked.

aggressive b-cell non-hodgkin lymphoma (anhl), dlbcl, fl, high-grade b-cell lymphoma (hgbcl), indolent b-cell non-hodgkin lymphoma (inhl), marginal zone lymphoma (mzl), mcl, primary mediastinal large b-cell lymphoma (pmbcl), small lymphocytic lymphoma (sll)